Skip to content
DataLookout
Menu

ADAPT JrNCT04833894

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

StatusActive, Not Recruiting
PhasePhase 2/3
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 26 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 26 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 15 participants (planned 12)
    • Secondary endpoints: details revised at 2 of 19 entries
    • Site details revised at 25 of 25 sites
  2. Minor Study sites: 24 to 25v25
  3. Minor Site details revised at 2 of 24 sitesv24
  4. Minor Site details revised at 5 of 24 sitesv23
  5. Notable Primary and study completion dates: Aug 2024 to Mar 2027
    • Site contacts updated at 6 of 24 sites
    v22
Show 20 earlier versionsHide 20 earlier versions
  1. Minor Study sites revised (24)v21
  2. Minor Study sites: 23 to 24
    • Primary and study completion dates: Mar 2024 to Aug 2024
    v20
  3. Minor Study sites: 22 to 23v19
  4. Minor Study sites revised (22)v18
  5. Minor Site details revised at 2 of 22 sitesv17
  6. Minor Study sites: 20 to 22v16
  7. Notable Eligibility criteria shortened, about 36 wordsv15
  8. Minor Site details revised at 1 of 20 sitesv14
  9. Minor Study sites: 18 to 20v13
  10. Minor Study sites: 17 to 18v12
  11. Notable Primary and study completion dates pushed to Mar 2024
    • Study sites: 16 to 17
    v11
  12. Minor Study sites: 15 to 16v10
  13. Minor Study sites: 14 to 15v9
  14. Minor Study sites: 13 to 14v8
  15. Minor Study sites: 12 to 13v7
  16. Minor Study sites: 9 to 12v6
  17. Minor Study sites: 6 to 9v5
  18. Minor Study sites: 3 to 6v4
  19. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Jul 30, 2021 to Oct 26, 2021
    v3
  20. Notable Primary completion date: Oct 31, 2024 to Dec 31, 2022v2 Show 4 more changesShow less
    • Start date: May 30, 2021 to Jul 30, 2021
    • Eligibility criteria expanded, about 47 words
    • Study completion date: Apr 30, 2025 to Mar 30, 2023
    • Secondary endpoints revised (19)
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)
Timeframe: up to 26 weeks
Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)
Timeframe: up to 26 weeks
Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis
Timeframe: up to 26 weeks
Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis
Timeframe: up to 26 weeks

Secondary (19)

Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)
Efgartigimod serum concentrations from blood samples
Absolute values of levels of total Immunoglobulin G (IgG) from blood samples
Change from baseline of levels of total Immunoglobulin G (IgG) from blood samples
Percentage change from baseline of total Immunoglobulin G (IgG) from blood samples
Show 14 moreShow less
Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Percentage change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples
Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples
Absolute values of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.
Change from baseline of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.
Absolute values of total Quantitative Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.
Change from baseline of total Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.
Absolute values of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)
Change from baseline of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)
Values of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire
Change from baseline of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire
Change in protective antibody titers to vaccines received before or during the trial from blood samples

Arms and interventions

EfgartigimodExperimental

Patients receiving efgartigimod intravenous (IV) treatment

Biologicals: Efgartigimod IV

Sites

25 sites in 12 countries

Italy 3, Poland 3, United Kingdom 3, United States 3, Canada 2, France 2, Georgia 2, Germany 2, Spain 2, Austria 1, Belgium 1, Netherlands 1